Biography

• Dr. Jia is an academician of the Chinese Academy of Engineering, member of the Chinese Academy of Medical Sciences, director of the Shanghai Diabetes Institute, director of the National office for primary diabetes care, and chief editor of the Chinese Journal of Internal Medicine. She has published over 300 original articles as first and/or corresponding authors in journals, including BMJ, Lancet Diabetes Endocrinol, Cell Metab, Nat Biotechnol, Sci Transl Med, Diabetes, Diabetes Care, J Hepatol, etc. She has been awarded the national science and technology progress prizes, the provincial science and technology progress prizes, the Xiaoren Pan distinguished research prize for epidemiology of diabetes in Asia, the Ho Leung Ho Lee Foundation science and technology prize, and the Tan Jiazhen life science prize, etc.

• Her research achievements include the followings: Develop genetic models for people with type 2 diabetes, to early detect and warning high-risk people with diabetes among Chinese. Establish new diagnostic standards for abdominal obesity among Chinese, and continuous glucose monitoring standards globally, to promote the use of new personalized treatment technologies. Develop a hospital-community integrated management model for diabetes care, and a deep learning system for detecting diabetic complications, to promote the comprehensive diabetes prevention, treatment and management system in primary care. The Lancet Diabetes Endocrinol remarked, “Jia’s work is remarkable in integrating the worlds of specialty care with community health centres. This and her work integrating genetics with clinical care reflect her early interest in engineering.” The president of the American Endocrine Society remarked, “Professor Jia and her colleagues have been international leaders in the use of continuous glucose monitoring standards. ”

Publications

1. Leung H, Long X, Ni Y*, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H*, Jia W*, Panagiotou G*. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022;14(648):eabk0855.

2. Ye X, Yu R, Jiang F, Hou X*, Wei L, Bao Y, Jia W*. Osteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study. Diabetes Care. 2022;45(4):830-836.

3. Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia W*, Jiang C*, Jia W*. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021; 33(4):791-803.

4. Shen Y, Fan X, Zhang L, Wang Y, Li C, Lu J, Zha B, Wu Y, Chen X, Zhou J*, Jia W*. Thresholds of glycemia and the outcomes of COVID-19 complicated with diabetes:a retrospective exploratory study using continuous glucose monitoring. Diabetes Care. 2021; 44(4):976-982.

5. Li S, Yu H, Zhang P, Tu Y, Xiao Y, Yang D, Bao Y, Han J*, Jia W*. The nonlinear relationship between psoas cross-sectional area and BMI: a new observation and its insights into diabetes remission after roux-en-Y gastric bypass. Diabetes Care. 2021; 44(12):2783-2786.

6. Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang M, Gao Q, Zhang Y, Ni J, Hou X, Bao Y, Kovatcheva-Datchary P, Xu A, Li H*, Panagiotou G*, Jia W*. Decreased abundance of akkermansia muciniphila leads to the impairment of insulin secretion and glucose homeostasis in lean type 2 diabetes. Adv Sci. 2021;8(16): e2100536.

7. Dai L, Wu L, Li H, Cai C, Wu Q, Kong H, Liu R, Wang X, Hou X, Liu Y, Long X, Wen Y, Lu L, Shen Y, Chen Y, Shen D, Yang X, Zou H*, Sheng B*, Jia W*. A deep learning system for detecting diabetic retinopathy across the disease spectrum. Nat Commun. 2021;12: 3242.

8. Zheng X, Chen T, Zhao A, Ning Z, Kuang J, Wang S, You Y, Bao Y, Ma X, Yu H, Zhou J, Jiang M, Li M, Wang J, Ma X, Zhou S, Li Y, Ge K, Rajani C, Xie G, Hu C, Guo Y, Lu A*, Jia W*, Jia W*. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat Commun. 2021;12:1487.

9. Ji L*, Song W, Fang H, Li W, Geng J, Wang Y, Guo L, Cai H, Yang T, Li H, Yang G, Li Q, Liu K, Li S, Liu Y, Shi F, Li X, Gao X, Tian H, Ji Q, Su Q, Zhou Z, Wang W, Zhou Z, Li X, Xu Y, Ning Z, Cao H, Pan D, Yao H, Lu X, Jia W*. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Science Bulletin. 2021;66(15):1571-80.

10. Jia W*, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L*. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Science Bulletin. 2021;66(15):1581-1590.

11. Jia W*, Zhang P, Zhu D, Duolikun N, Li H, Bao Y, Li X, ROADMAP Study Group. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): a cluster randomized trial. PLoS Med. 2021;18(9): e1003754.

12. Chen D, Zhao X, Sui Z, Niu H, Chen L, Hu C, Xuan Q, Hou X, Zhang R, Zhou L, Li Y, Yuan H, Zhang Y, Wu J, Zhang L*, Wu R*, Piao HL*, Xu G*, Jia W*. A multi-omics investigation of the molecular characteristics and classification of six metabolic syndrome relevant diseases. Theranostics. 2020;10(5):2029-2046.

13. Zhang SQ, Ma KY, Schonnesen AA, Zhang M, He C, Sun E, Williams CM, Jia W*, Jiang N*. High-throughput determination of the antigen specificities of T cell receptors in single cells. Nat Biotechnol. 2018 Nov 12. doi: 10.1038/nbt.4282.

14. Li H, Wu G, Fang Q, Zhang M, Hui X, Sheng B, Wu L, Bao Y, Li P, Xu A*, Jia W*. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun. 2018 Jan 18;9(1):272.

15. Lu J, Ma X, Zhou J*, Zhang L, Mo Y, Ying L, Lu W, Zhu W, Bao Y, Vigersky RA, Jia W*. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018 Nov;41(11):2370-2376.

16. Hu C, Jia W*. Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication. Diabetes. 2018 Jan;67(1):3-11. doi: 10.2337/dbi17-0013.

17. Hou X, Chen P, Hu G, Chen Y, Chen S, Ma X, Chen L, Yang Z, Yang W, Jia W*. Cardiometabolic Disease Is Prevalent in Normal-Weight Chinese Adults. China National Diabetes and Metabolic Disorders Study Group. J Am Coll Cardiol. 2016 Oct 4;68(14):1599-600.

18. Yan J, Peng D, Jiang F, Zhang R, Chen M, Wang T, Yan D, Wang S, Hou X, Bao Y, Hu C*, Jia W*. Impaired pancreatic beta cell compensatory function is the main cause of type 2 diabetes in individuals with high genetic risk: a 9 year prospective cohort study in the Chinese population. Diabetologia. 2016 Jul;59(7):1458-1462.

19. Jia W*, Xiao X, Ji Q, Ahn KJ, Chuang LM, Bao Y, Pang C, Chen L, Gao F, Tu Y, Li P, Yang J. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015 Apr;3(4):254-62.

20. Peng D, Wang J, Zhang R, Jiang F, Tang S, Chen M, Yan J, Sun X, Wang S, Wang T, Yan D, Bao Y, Hu C*, Jia W*. Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1231-8.

21. Ma RC*, Lin X*, Jia W*. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014 Dec;2(12):980-91.

22. Liu F, Chen DD, Sun X, Xie HH, Yuan H, Jia W*, Chen AF*. Hydrogen Sulfide Improves Wound Healing via Restoration of Endothelial Progenitor Cell Functions and Activation of Angiopoietin-1 in Type 2 Diabetes. Diabetes. 2014 Jan 31.

23. Fang Q, Yang W, Li H, Hu W, Chen L, Jiang S, Dong K, Song Q, Wang C, Chen S, Liu F, Jia W*. Negative regulation of DsbA-L gene expression by the transcription factor Sp1. Diabetes. 2014 Dec;63(12):4165-71

24. Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, Jia W*. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China. J Hepatol. 2013 Mar;58(3):557-63.

25. Fang Q, Li H, Song Q, Yang W, Hou X, Ma X, Lu J, Xu A, Jia W*. Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels. Diabetes Care. 2013 Sep;36(9):2810-4.

26. Li M*, Chen S*, Li Y, Chen Y, Cheng Y, Hu D, Tan H, Wu Q, Wang W, Sun Z, Wei X, Zhang J, Qiao R, Zong W, Zhang Y, Lou W, Chen Z, Zhu Y, Peng D, Ding S, Xu X, Hou X, Jia W*. Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. Ann Intern Med. 2013 Oct 15;159(8):514-21.

27. Wang C, Li X, Mu K, Li L, Wang S, Zhu Y, Zhang M, Ryu J, Xie Z, Shi D, Zhang WJ, Dong LQ*, Jia W*. Deficiency of APPL1 in mice impairs glucose-stimulated insulin secretion through inhibition of pancreatic beta cell mitochondrial function. Diabetologia. 2013 Sep;56(9):1999-2009.

28. Li H, Gao Z, Zhang J, Ye X, Xu A, Ye J*, Jia W*. Sodium Butyrate Stimulates Expression of Fibroblast Growth Factor 21 in Liver by Inhibition of Histone Deacetylase 3. Diabetes. 2012, 61(4):797-806.

29. Hu C, Zhang R, Wang C, Wang J, Pang C, Ma X, Bao Y, Xiang K, Jia W*. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetes patients. Diabetes 2011, 60(11):3085-3089.

30. Yu W, Hu C, Zhang R, Wang C, Qin W, Lu J, Jiang F, Tang S, Bao Y, Xiang K, Jia W*. Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes. Clin Pharmacol Ther. 2011 Mar;89(3):437-42. Epub 2011 Feb 2.

31. Bao Y, Ma X, Li H, Zhou M, Hu C, Wu H, Tang J, Hou X, Xiang K, Jia W*. Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ. 2010 May 17;340:c2249-57.

32. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W*. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010 53(5):934-940.

33. Hu C, Wang C, Zhang R, Ng MC, Bao Y, Wang C, So WY, Ma RC, Ma X, Chan JC, Xiang K, Jia W*. Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population. Diabetologia. 2010 Feb;53(2):290-8. Epub 2009 Nov 24.

34. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W*. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care. 2009 Jul;32(7):1188-93.

35. Hu C, Wang C, Zhang R, Ma X, Wang J, Lu J, Qin W, Bao Y, Xiang K, Jia W*. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia. 2009 Jul;52(7):1322-5.

36. Hu C, Zhang R, Wang C, Ma X, Wang C, Fang Q, Bao Y, Xiang K, Jia W*. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia. 2009 Mar;52(3):451-6.

37. Jia W*, Pang C, Chen L, Bao Y, Lu JX, Lu HJ, Tang JL, Wu YM, Zuo YH, Jiang SY, Xiang KS. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007 Feb;50(2):286-292.

院士英文简介

• Expert in endocrinology and metabolism, and chronic disease prevention, treatment and management, mainly engaged in precision medicine, early warning and screening, pathogenesis research, and the integration model of prevention, treatment, and management in the research area of diabetes. Born in November 1956, with ancestral home in Zhenjiang City, Jiangsu Province. In 2003, she received her Ph.D. from the Shanghai Jiao Tong University School of Medicine (formerly as the Shanghai Second Medical University).

• In 2021, she was elected as an academician of the Chinese Academy of Engineering.